Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis

Parasite Immunology

Volumn 37, Issue 4, 2015, Pages 192-203

  Kaur, H ^a   Thakur, A ^a   Kaur, S ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

31kDa; 36 kDa; 51 kDa; Immune response; Vaccines; Visceral leishmaniasis

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; PARASITE ANTIGEN; POLYPEPTIDE; SAPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA DONOVANI; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROMASTIGOTE; TH1 CELL; VISCERAL LEISHMANIASIS; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; LEISHMANIASIS, VISCERAL;

LEISHMANIA DONOVANI; MURINAE; MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CYTOKINES; FEMALE; IMMUNOGLOBULIN G; LEISHMANIA DONOVANI; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MALE; MICE; MICE, INBRED BALB C; PARASITE LOAD; SAPONINS;

EID: 84924808604     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12176     Document Type: Article

References (62)

1. Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 2012; 7: e35671.
2. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-318.
3. Sundar S. Drug resistances in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6: 849-854.
4. Murray HW, Berman JD, Davies CR & Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-1577.
5. Croft SL, Barret MP & Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005; 21: 508-512.
6. Natera S, Machuca C, Padrón-Nieves M, Romero A, Díaz E & Ponte-Sucre A. Leishmania spp: proficiency of drug-resistant parasites. Int J Antimicrob Agents 2007; 29: 637-642.
7. World Health Organization [Internet]. Geneva, Switzerland; 2011. Available from: http://www.who.int/leishmaniasis/en/index.html.
8. Breton M, Tremblay MJ, Ouellette M & Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 2005; 73: 6372-6382.
9. Mutiso JM, Macharia JC & Gicheru MM. A review of adjuvants for Leishmania vaccine candidates. J Biomed Res 2010; 24: 16-25.
10. Handman E, Schnur LF, Spithill TW & Mitchell GF. Passive transfer of Leishmania lipopolysaccharide confers parasite survival in macrophages. J Immunol 1986; 137: 3608-3613.
11. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR & Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette- Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 1993; 90: 11473-11477.
12. McMohan-Pratt D, Rodriguez D, Rodriguez JR, et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 1993; 61: 3351-3359.
13. Mougneau E, Altare F, Wakil AE, et al. Expression cloning of a protective Leishmania antigen. Science 1995; 268: 563-566.
14. Rafati S, Baba AA, Bakhshayesh M & Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin Exp Immunol 2000; 120: 134-138.
15. Dole VS, Raj VS, Ghosh A, Madhubala R, Myler PJ & Stuart KD Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 2000; 19: 423-430.
16. Stager S, Smith DF & Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 2000; 165: 7064-7071.
17. Wilson ME, Young BM, Anderson KP, et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 1995; 63: 2062-2069.
18. Valenzuela JG, Belkaid Y, Garfield MK, et al. Characterization of a protective salivary protein. J Exp Med 2001; 194: 331-342.
19. Champsi J & McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 1988; 56: 3272-3279.
20. Webb JR, Campos-Neto A, Ovendale PJ, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66: 3279-3289.
21. Lohman KL, Langer PJ & McMahon-Pratt D. Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis. Proc Natl Acad Sci USA 1990; 87: 8393-8397.
22. De Souza E, Bernardo RR, Palatnik M & De Sousa CBP. Vaccination of BALB/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 2001; 19: 3104-3115.
23. Bhowmick S & Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine mediated protection in visceral leishmaniasis. PLoS ONE 2009; 4: e5820.
24. Kaur T, Sobti RC & Kaur S. Cocktail of gp63 and Hsp70 induces protection against Leishmania donovani in BALB/c mice. Parasite Immunol 2011; 33: 95-103.
25. Nagill R & Kaur S. Enhanced efficacy and immunogenicity of 78 kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine 2010; 28: 4002-4012.
26. Sparg SG, Light ME & Van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol 2004; 94: 219-243.
27. Lacaille-Dubois MA. Bioactive saponins with cancer related and immunomodulatory activity: recent developments. Stud Nat Prod Chem 2005; 32: 209-246.
28. Skene CD & Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 2006; 40: 53-59.
29. Scott MT, Bahr G, Modabber F & Chedid L. Adjuvant requirement for protective immunization of mice using Trypanosoma cuzi 90K cell surface glycoprotein. Int Arch Allergy Appl Immunol 1984; 74: 373-377.
30. Britt W, Fay J, Seals J & Kensil C. Formulation of an immunogenic human cytomegalovirus vaccine: response in mice. J Infect Dis 1995; 171: 18-25.
31. Khan IA, Ely KH & Kasper LH. A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. J Immunol 1991; 147: 3501-3506.
32. Glaueri AM, Dingle JT & Lucy JA. Action of saponins on biologic membranes. Nature 1962; 196: 953-959.
33. Sun HX, Pan HJ & Pan YJ. Haemolytic activities and immunologic adjuvant effect of Panax notoginseng saponins. Acta Pharmacol 2003; 24: 1150-1154.
34. Coler RN & Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005; 21: 244-249.
35. (clinicaltrials.gov/show/NCT01751048).
36. Bradley DJ & Kirkley J. Regulation of Leishmania population within host 1. The variable course of L. donovani infections in mice. Clin Exp Immunol 1977; 30: 119-129.
37. Kaur S, Kaur T, Garg N, Mukherjee S, Raina P & Athokpam V Effect of dose and route of inoculation on the generation of CD4+ Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 2008; 103: 1413-1419.
38. Ravindran R, Anam K, Bairagi BC, et al. Characterization of immunoglobulin and its subclass response to Indian Kala Azar infection before and after chemotherapy. Infect Immun 2004; 72: 863-870.
39. Srivastava P, Prajapati VK, Rai M & Sundar S. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J Clin Microbiol 2011; 49: 3088-3091.
40. Goto Y, Bogatzki LY, Bertholet S, Coler RN & Reed SG. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007; 25: 7450-7458.
41. Carrillo E, Crusat M, Nieto J, et al. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 2008; 26: 1902-1911.
42. Agallou M, Margaroni M & Karagouni E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 2011; 29: 5053-5064.
43. Ghosh A, Zhang WW & Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 2001; 20: 59-66.
44. Skeiky YA, Kennedy M, Kaufman D, et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998; 161: 6171-6179.
45. Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S & Reed SG. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am J Trop Med Hyg 2010; 82: 808-813.
46. Singh OP, Stober CB, Singh AK, Blackwell JM & Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLoS Negl Trop Dis 2012; 6: e1874.
47. Molano I, Garcia AM, Miron C, et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 2003; 92: 1-13.
48. Hamid MN, Simin SK & Davood I. Leishmania tropica infection in comparison to Leishmania major induces lower delayed type hypersensitivity in BALB/c mice. Korean J Parasitol 2007; 45: 103-109.
49. Dannenberg JAM. Delayed-type hypersensitivity and cell mediated immunity in the pathogenesis of tuberculosis. Immunol Today 1991; 12: 228-233.
50. Kumari S, Samanta M, Misraa P, et al. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine 2008; 26: 5700-5711.
51. Carvalho EM, Johnson WD, Barreto E, et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144-4148.
52. Scott P, Natovitz P, Coffman RL, Pearce E & Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168: 1675-1684.
53. Muller I, Kropf P, Etges RJ & Louis JA. Gamma interferon response in secondary Leishmania major infection: role of CD8+ T cells. Infect Immun 1993; 61: 3730-3738.
54. Ramirez L, Corvo L, Duarte MC, et al. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. Parasit Vectors 2014; 7: 3.
55. Coler RN, Goto Y, Bogatzki L, Raman V & Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007; 75: 4648-4654.
56. Coffman RL, Lebman DA & Rothman P. Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol 1993; 54: 229-270.
57. Ghose AC, Haldar JP, Pal SC, Mishra BP & Mishra KK. Serological investigations on Indian kala-azar. Clin Exp Immunol 1980; 40: 318-326.
58. Deak E, Jayakumar A, Cho KW, et al. Murine visceral leishmaniasis: IgM and polyclonal B-cell activation lead to disease exacerbation. Eur J Immunol 2010; 40: 1355-1368.
59. Ferreira JHL, Silva LDS, Longo-Maugèri IM, Katz S & Barbièri CL. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the immunotherapy of canine visceral leishmaniasis. Plos Neg Trop Dis 2014; 8: e2729.
60. Kaur J, Kaur T & Kaur S. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice. Acta Trop 2011; 119: 50-56.
61. Rafati S, Salmanian AH, Taheri T, Vafa M & Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 2001; 19: 3369-3375.
62. Thakur A, Kaur H & Kaur S. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis. Parasitol Int 2015; 64: 70-78.